Atara Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on June 20, 2024. The report details a material corporate action involving the Company's capital structure, specifically a reverse stock split of its common stock.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the execution of the reverse stock split.
Material Changes
- Reverse Stock Split: The Company effected a one-for-twenty-five (1:25) reverse stock split effective at 12:01 a.m. Eastern Time on June 20, 2024.
- Shareholder Approval: The split ratio was approved by stockholders at the annual meeting on June 10, 2024, within an authorized range of 1:4 to 1:30.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on June 20, 2024, under a new CUSIP number (046513206).
- Fractional Shares: No fractional shares or warrants were issued. Holders entitled to fractional amounts received cash payments based on the closing price on the last trading day prior to the effective date.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors beyond the standard disclosure that the description of the Charter Amendment is qualified by the full text of the Amendment filed as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the new CUSIP number (046513206) for trading purposes.
- Confirm the receipt of cash payments for any fractional shares or warrants resulting from the 1:25 split ratio.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal details regarding the Charter changes.
- Check the adjusted share count and price per share on Nasdaq following the June 20, 2024 effective date.